Evidence map›Paper›PMID 41171411›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026

Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation.

Luchang Cui, Juhong Lee, Juliet Miller, Minmeng Tang, Sajjad Abedian, Nasser K Altorki, Robert S Crupi, Lauren Groner, Neal I Lindeman, Laura C Pinheiro and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Luchang CuiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0009-0002-6219-3920
Juhong LeeInformation Technologies and Services Department, Weill Cornell Medicine, New York, New York.ORCID 0009-0006-9853-604X
Juliet MillerDepartment of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0009-0007-7017-4814
Minmeng TangSchool of Civil and Environmental Engineering, Cornell University, Ithaca, New York.ORCID 0000-0002-2848-9712
Sajjad AbedianInformation Technologies and Services Department, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0411-5185
Nasser K AltorkiDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9754-9945
Robert S CrupiNewYork-Presbyterian Queens, New York, New York.ORCID 0009-0000-3800-0653
Lauren GronerDepartment of Radiology, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-6017-3470
Neal I LindemanDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-7092-6859
Laura C PinheiroDepartment of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-6920-8526
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-2306-8668
Jonathan Villena-VargasDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-8248-666X
Anil VachaniDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-3871-8697
Julie A BartaDepartment of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-6480-0769
H Oliver GaoSchool of Civil and Environmental Engineering, Cornell University, Ithaca, New York.ORCID 0000-0002-7861-9634
Evan SholleDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9518-4399
James P SolomonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-3496-1005
Christine A GarciaDepartment of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0367-7813
Eunji ChoiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-1315-1433
Yiwey ShiehDepartment of Population Health Sciences, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-0159-7748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe proportion of lung cancers affecting individuals who have never smoked is growing, with these cancers being prone to harbor mutations in the EGFR gene. Little is known about risk factors and prognostic indicators for EGFR-mutant cancers, with current research limited by the scarcity of datasets integrating genomic, clinical, and environmental data.

methodsWe created the Meyer Cancer Center Molecularly Enhanced Lung Cancer Database (MCC-MELD), including lung cancer cases from a large catchment area in New York City. We identified cases through linkage to our institution's cancer registry and a clinician-initiated, manually curated database. We linked all cases to the electronic health record and in-house tumor genomic testing results. We used natural language processing (NLP) to extract unstructured genomic testing results and detailed smoking history. We linked geocoded addresses to detailed area-level measures.

resultsMCC-MELD contains 9,573 patients with lung cancer diagnosed from 1988 to 2024, of whom 20% were non-Hispanic Asian, 14% were non-Hispanic Black, and 8% were Hispanic. We identified 1,092 (11.4%) EGFR-mutant cancers, with NLP identifying 397 cases not identified by structured data. NLP showed high accuracy in ascertaining EGFR status (97%) and quantitative smoking history variables (90%-98%). Never smokers made up 16% of the cases in MCC-MELD.

conclusionsMCC-MELD is an NLP-enhanced database containing clinical information, genomic testing results, and linkages to area-level data for patients with lung cancer from a diverse urban setting. IMPACT: This resource can facilitate studies on lung cancer risk factors, treatment patterns, and outcomes by EGFR and other driver mutation status.

Indexed as

Lung NeoplasmsRegistriesAgedErbB ReceptorsFemaleGenomicsHumansMaleMiddle AgedMutationNew York CityRisk FactorsEGFR protein, humanErbB Receptors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.